Aries Wealth Management Increases Position in Johnson & Johnson (NYSE:JNJ)

Aries Wealth Management raised its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,985 shares of the company’s stock after buying an additional 273 shares during the period. Johnson & Johnson accounts for about 2.4% of Aries Wealth Management’s portfolio, making the stock its 7th largest holding. Aries Wealth Management’s holdings in Johnson & Johnson were worth $5,390,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC boosted its stake in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after acquiring an additional 78 shares during the period. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $39,000. First Bank & Trust increased its position in Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after buying an additional 156 shares during the period. Heritage Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $84,000. Finally, Timber Creek Capital Management LLC increased its position in Johnson & Johnson by 225.0% during the third quarter. Timber Creek Capital Management LLC now owns 650 shares of the company’s stock worth $106,000 after acquiring an additional 450 shares during the period. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.31 on Wednesday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The firm has a market cap of $440.04 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The company has a 50 day simple moving average of $175.98 and a 200 day simple moving average of $171.06.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. Johnson & Johnson’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.13 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a dividend of $1.13 per share. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s payout ratio is 62.95%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on JNJ shares. Barclays initiated coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price on the stock. StockNews.com began coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Morgan Stanley dropped their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Citigroup increased their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Finally, Sanford C. Bernstein cut their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $181.75.

Insiders Place Their Bets

In related news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The disclosure for this sale can be found here. Over the last three months, insiders sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.